Overview
AGIO market data
Price History
AGIO price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for AGIO. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Agios Reports Neutral Sickle Cell Data, Decides To Stop DevelopmentBenzinga · Jul 21, 2026, 3:44 PM
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $52Benzinga · Jul 21, 2026, 3:31 PM
Agios Pharmaceutical shares are trading lower after the company announced topline results from its Phase 2 trial of tebapivat. Phase 2 results did not establish a differentiated profile to support continued development in sickle cell disease.Benzinga · Jul 21, 2026, 1:17 PM
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · Jul 21, 2026, 12:01 PM
Agios Pharma Announces Topline Results From Phase 2 Trial Of Tebapivat, Oral Pyruvate Kinase Activator, In Patients Aged 16 Years Or Older With Sickle Cell DiseaseBenzinga · Jul 21, 2026, 11:04 AM
Why Is Agios Pharma Stock Soaring Tuesday?Benzinga · Jul 7, 2026, 6:35 PM
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)The Motley Fool · Jul 7, 2026, 5:15 PM
RBC Capital Maintains Sector Perform on Agios Pharmaceuticals, Raises Price Target to $32Benzinga · Jul 7, 2026, 3:55 PM
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On TuesdayBenzinga · Jul 7, 2026, 2:05 PM
Truist Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $41Benzinga · Jul 7, 2026, 12:25 PM